These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 8869018

  • 1. An overview of the results of the EPIC trial.
    Califf RM, Lincoff AM, Tcheng JE, Topol EJ.
    Eur Heart J; 1995 Nov; 16 Suppl L():43-9. PubMed ID: 8869018
    [Abstract] [Full Text] [Related]

  • 2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
    EPIC Investigators.
    N Engl J Med; 1994 Apr 07; 330(14):956-61. PubMed ID: 8121459
    [Abstract] [Full Text] [Related]

  • 3. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications.
    Lefkovits J, Blankenship JC, Anderson KM, Stoner GL, Talley JD, Worley SJ, Weisman HF, Califf RM, Topol EJ.
    J Am Coll Cardiol; 1996 Oct 07; 28(4):849-55. PubMed ID: 8837559
    [Abstract] [Full Text] [Related]

  • 4. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
    Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ.
    J Am Coll Cardiol; 1997 Jul 07; 30(1):149-56. PubMed ID: 9207636
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
    Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf RA, Topol EJ.
    Am J Cardiol; 1998 Jul 01; 82(1):7-12. PubMed ID: 9671000
    [Abstract] [Full Text] [Related]

  • 7. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.
    Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M.
    Lancet; 1994 Apr 09; 343(8902):881-6. PubMed ID: 7908357
    [Abstract] [Full Text] [Related]

  • 8. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
    Mak KH, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ.
    Am J Cardiol; 1997 Oct 15; 80(8):985-8. PubMed ID: 9352964
    [Abstract] [Full Text] [Related]

  • 9. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
    Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM.
    JAMA; 1997 Aug 13; 278(6):479-84. PubMed ID: 9256222
    [Abstract] [Full Text] [Related]

  • 10. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Eur Heart J; 1998 Apr 13; 19 Suppl D():D10-21. PubMed ID: 9597518
    [Abstract] [Full Text] [Related]

  • 11. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG InvestigatorsDepartment of Cardiology, Cleveland Clinic Foundation, OH 44195, USA..
    N Engl J Med; 1997 Jun 12; 336(24):1689-96. PubMed ID: 9182212
    [Abstract] [Full Text] [Related]

  • 12. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Marmur JD, Mitre CA, Barnathan E, Cavusoglu E.
    Am Heart J; 2006 Nov 12; 152(5):876-81. PubMed ID: 17070148
    [Abstract] [Full Text] [Related]

  • 13. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.
    Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF.
    Circulation; 1994 Feb 12; 89(2):596-603. PubMed ID: 7508826
    [Abstract] [Full Text] [Related]

  • 14. A risk-benefit assessment of abciximab in angioplasty.
    Kleiman NS.
    Drug Saf; 1999 Jan 12; 20(1):43-57. PubMed ID: 9935276
    [Abstract] [Full Text] [Related]

  • 15. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study.
    Lancet; 1997 May 17; 349(9063):1429-35. PubMed ID: 9164316
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
    Chen YH, Chen JW, Wu TC, Ding PY, Wang SP, Chang MS.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan 17; 63(1):8-15. PubMed ID: 10645045
    [Abstract] [Full Text] [Related]

  • 17. [Use of abciximab during coronary angioplasty].
    Philippe F, Montalescot G, Drobinski G, Thomas D.
    Arch Mal Coeur Vaiss; 1997 Dec 17; 90(12):1645-50. PubMed ID: 9587446
    [Abstract] [Full Text] [Related]

  • 18. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
    Ibbotson T, McGavin JK, Goa KL.
    Drugs; 2003 Dec 17; 63(11):1121-63. PubMed ID: 12749745
    [Abstract] [Full Text] [Related]

  • 19. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group.
    Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, Topol EJ, Califf RM.
    J Am Coll Cardiol; 1998 Aug 17; 32(2):311-9. PubMed ID: 9708455
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.